文献速递胰腺与胆道疾病消化道肿瘤与早癌

欧洲胆管癌全景:ENSCCA登记处的诊断、预后和治疗见解

Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
PubMed 文献 · J Hepatol · 2022-02-12

ENSCCA登记处是一项多中心观察性研究,纳入2010-2019年组织学确诊的2234例胆管癌患者,比较肝内、肝门周围和远端胆管癌的临床过程。42.2%的患者诊断时为局部病变,29.4%为局部晚期,28.4%为转移性。手术切除者预后最佳,R0切除中位总生存期45.1个月;不可切除患者中,接受积极姑息治疗者中位总生存期10.6个月,最佳支持治疗者4.0个月。

要点

  • 诊断时42.2%为局部病变,29.4%为局部晚期,28.4%为转移性。
  • R0切除患者中位总生存期45.1个月,R1切除24.7个月,淋巴结侵犯23.3个月。
  • 不可切除患者中,积极姑息治疗中位总生存期10.6个月,最佳支持治疗4.0个月。

核心结论

  • 胆管癌常在晚期诊断,部分患者未能接受癌症特异性治疗,预后仍然很差。
  • 需要识别可预防的危险因素并在高危人群中实施监测,以降低癌症相关死亡率。

研究设计与样本

  • ENSCCA登记处是一项多中心观察性研究,纳入2010-2019年组织学确诊的胆管癌患者,共2234例(男/女=1.29)。
  • 研究进行人口学、组织形态学、生化和临床研究,比较肝内(iCCA)、肝门周围(pCCA)和远端(dCCA)胆管癌亚型。

主要发现

  • iCCA(n=1243)与超重/肥胖及包括肝硬化和/或病毒性肝炎的慢性肝病相关;pCCA(n=592)与原发性硬化性胆管炎相关;dCCA(n=399)与胆总管结石相关。
  • 诊断时42.2%患者为局部病变,29.4%为局部晚期疾病,28.4%为转移性疾病。
  • 血清CEA和CA19-9诊断敏感性低,但二者同时升高与局部晚期疾病风险增加相关(比值比2.16;95%CI 1.43-3.27),与转移性疾病风险增加相关(比值比5.88;95%CI 3.69-9.25)。
  • 接受切除的患者(50.3%)预后最佳,尤其是切缘阴性(R0)者(中位总生存期=45.1个月);切缘阳性(R1)(风险比1.92;95%CI 1.53-2.41;中位总生存期=24.7个月)和淋巴结侵犯(风险比2.13;95%CI 1.55-2.94;中位总生存期=23.3个月)损害预后。
  • 不可切除疾病患者(49.6%)中,接受积极姑息治疗(主要为化疗,26.2%)者中位总生存期为10.6个月,接受最佳支持治疗(20.6%)者为4.0个月;iCCA预后较p/dCCA差;ECOG体能状态、转移性疾病和CA19-9是独立预后因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose incidence and related mortality is increasing. This study investigates the clinical course of CCA and subtypes (intrahepatic [iCCA], perihilar [pCCA], and distal [dCCA]) in a pan-European cohort. METHODS: The ENSCCA Registry is a multicenter observational study. Patients were included if they had a histologically proven diagnosis of CCA between 2010-2019. Demographic, histomorphological, biochemical, and clinical studies were performed. RESULTS: Overall, 2,234 patients were enrolled (male/female=1.29). iCCA (n = 1,243) was associated with overweight/obesity and chronic liver diseases involving cirrhosis and/or viral hepatitis; pCCA (n = 592) with primary sclerosing cholangitis; and dCCA (n = 399) with choledocholithiasis. At diagnosis, 42.2% of patients had local disease, 29.4% locally advanced disease (LAD), and 28.4% metastatic disease (MD). Serum CEA and CA19-9 showed low diagnostic sensitivity, but their concomitant elevation was associated with increased risk of presenting with LAD (odds ratio 2.16; 95% CI 1.43-3.27) or MD (odds ratio 5.88; 95% CI 3.69-9.25). Patients undergoing resection (50.3%) had the best outcomes, particularly with negative-resection margin (R0) (median overall survival [mOS] = 45.1 months); however, margin involvement (R1) (hazard ratio 1.92; 95% CI 1.53-2.41; mOS = 24.7 months) and lymph node invasion (hazard ratio 2.13; 95% CI 1.55-2.94; mOS = 23.3 months) compromised prognosis. Among patients with unresectable disease (49.6%), the mOS was 10.6 months for those receiving active palliative therapies, mostly chemotherapy (26.2%), and 4.0 months for those receiving best supportive care (20.6%). iCCAs were associated with worse outcomes than p/dCCAs. ECOG performance status, MD and CA19-9 were independent prognostic factors. CONCLUSION: CCA is frequently diagnosed at an advanced stage, a proportion of patients fail to receive cancer-specific therapies, and prognosis remains dismal. Identification of preventable risk factors and implementation of surveillance in high-risk populations are required to decrease cancer-related mortality. LAY SUMMARY: This is, to date, the largest international (pan-European: 26 hospitals and 11 countries) observational study, in which the course of cholangiocarcinoma has been investigated, comparing the 3 subtypes based on the latest International Classification of Diseases 11th Edition (ICD-11) (i.e., intrahepatic [2C12], perihilar [2C18], or distal [2C15] affected bile ducts), which come into effect in 2022. General and tumor-type specific features at diagnosis, risk factors, biomarker accuracy, as well as patient management and outcomes, are presented and compared, outlining the current clinical state of cholangiocarcinoma in Europe.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022. PMID: 35167909. doi:10.1016/j.jhep.2021.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。